ReviewReviews in endocrine & metabolic disorders2026
Virtual reality interventions in obesity and eating disorders: a systematic review of biomarker, clinical, and behavioral outcomes.
Review in Reviews in endocrine & metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and eating disorders (EDs) are major public health challenges associated with high morbidity and mortality. This systematic review evaluated the effects of immersive virtual reality (VR) interventions on clinical outcomes and biomarker-domain outcomes in obesity and EDs. Following PRISMA 2020 guidelines, PubMed, Web of Science, and PsycINFO were searched through to April 2025. Eligible studies included immersive VR interventions targeting obesity or EDs and reporting at least one biomarker-domain outcome (anthropometric, physiological/autonomic, endocrine/metabolic, or neurocognitive/eye-tracking). Risk of bias was assessed using Joanna Briggs Institute tools. When at least three RCTs reported comparable outcomes, random-effects meta-analyses were performed. Twenty-three studies met the inclusion criteria (11 obesity, 12 EDs). ED studies included anorexia nervosa, bulimia nervosa, and binge-eating disorder. In obesity, VR-enhanced cognitive-behavioral therapy (VR-CBT) was associated with weight-loss maintenance, while VR-based exercise interventions were associated with short-term reductions in BMI and body weight. A meta-analysis of four RCTs showed a significant pooled effect of VR compared with control on anthropometric outcomes (Hedges' g = - 0.35, 95% CI [-0.61, - 0.09], p = .009; I² = 0%), with a numerically larger effect for VR-CBT. In EDs, VR-CBT was associated with reductions in body image disturbance and fear of weight gain, while VR cue-exposure therapy was linked to decreases in binge and purge frequency. Eye-tracking measures indicated attentional biases toward disorder-relevant cues, and autonomic and endocrine markers suggested VR's ability to elicit measurable psychophysiological responses. Overall, immersive VR interventions show promising but still preliminary effects across anthropometric, neurocognitive, and selected psychophysiological outcomes in obesity and EDs. Conclusions are constrained by small samples, heterogeneity within the interventions and outcome definitions, and a limited randomized evidence base (particularly in EDs). Larger biomarker-integrated trials with standardized measurement protocols and longer follow-up are needed to confirm efficacy and clarify mechanisms.
Indexed as
Identifiers
42165996What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.